WHAT WE OFFER
The Next Generation
of Small Molecules
Our technologies systematize discovery of first-in-class small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, we are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.

DISCOVERY PLATFORM
We are building tailor-made multi-omics datasets across inflammatory, fibrotic, and neurological diseases to power discovery campaigns on our platform. Partner with us to rapidly bolster your early-stage pipeline.

LICENSING
Using our end-to-end discovery capabilities, we are actively developing multiple leads towards IND-enabling studies and validating target candidates discovered through our platform. Get in touch to learn more about our pipeline and explore opportunities to expand your portfolio.
how we do it
We Solve Fundamental Challenges in Natural Product Drug Discovery with Advanced Technologies
bioedge
MOA-driven hypotheses
Integrates multiple data streams to nominate high-confidence therapeutic hypotheses, target candidates, and mechanisms of action.
nomad
Cloud-scale dereplication
Rapidly executes “cloud-scale” dereplication to identify novel scaffolds for actionable lead identification.
maiden
Bioactive Lead Identification
Deconvolutes bioactive lead molecules 100X faster than traditional methods and nominates high-value SAR directions.
Hi, We’re Enveda
At Enveda, we not only value the internal partnerships among our scientists, we also believe those lasting relationships are essential to success and speedy delivery of novel medicines to patients. We have built a drug discovery team of biologists, chemists, bioinformaticians, and data scientists who are full-time employees and part owners of Enveda Biosciences. Spanning three continents and six time-zones, we are all united by our purpose to deliver new treatments, and hope, to every patient.

Our Promise
to Nature
To Enveda, Earth’s biodiversity is a valuable source of inspiration for drug discovery. Our pledge to share fairly, on mutually agreed terms, benefits from the use of biological resources is the ethical foundation of our company. We are deeply committed to compliance with the Convention on Biological Diversity and the Nagoya protocol, and the rights of countries, indigenous peoples, and local communities to their plant resources. We are, together with our partners, dedicated to applying our R&D capabilities in a sustainable manner. Please contact us to discover how we develop solutions to today’s biggest healthcare challenges while ensuring the conservation, sustainable use, and equitable sharing of benefits from Earth’s biodiversity.
News & Views
A Recursion veteran is mapping plant life to chart a course to new therapies — and investors like what they see
One of the earliest employees at AI biotech Recursion Pharmaceuticals is leading a new company, and he’s just closed a hefty Series A to get things moving. Enveda Biosciences pulled in $51 million in the raise, the company announced Tuesday morning, with the goal of pushing some of its preclinical programs further along.
One of the earliest employees at AI biotech Recursion Pharmaceuticals is leading a new company, and he’s just closed a hefty Series A to get things moving. Enveda Biosciences pulled in $51 million in the raise, the company announced Tuesday morning, with the goal of pushing some of its preclinical programs further along.
Lux Capital Leads $51 Million Financing in Biotech Startup Enveda - Company searches for compounds from nature to develop medications
Lux Capital has led a $51 million venture-capital financing in Enveda Biosciences Inc., a biotechnology startup led by an entrepreneur who previously helped build another successful life-sciences company in Lux’s portfolio.
Lux Capital has led a $51 million venture-capital financing in Enveda Biosciences Inc., a biotechnology startup led by an entrepreneur who previously helped build another successful life-sciences company in Lux’s portfolio.
Enveda Biosciences Closes $51M Series A Financing Led by Lux Capital
BOULDER, Colo.–(BUSINESS WIRE)–Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-gen small molecule therapeutics, today announced an oversubscribed $51M Series A funding round. The financing was led by Lux Capital, with…
BOULDER, Colo.–(BUSINESS WIRE)–Enveda Biosciences, a leading biotechnology company harnessing the power of nature’s chemistry to develop next-gen small molecule therapeutics, today announced an oversubscribed $51M Series A funding round. The financing was led by Lux Capital, with…
Machine Learning will Revolutionize Metabolomics
We are at a junction where improvements in mass spectrometry equipment and computation workflows have enabled large amounts of data to be collected…
We are at a junction where improvements in mass spectrometry equipment and computation workflows have enabled large amounts of data to be collected…
Exploiting the Therapeutic Potential of Plants
Technology Networks recently interviewed Viswa Colluru, founder and CEO of Enveda Biosciences, to find out how the company is “harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges”…
Technology Networks recently interviewed Viswa Colluru, founder and CEO of Enveda Biosciences, to find out how the company is “harnessing the complexity of the natural world to tackle today’s biggest healthcare challenges”…
Drug Discovery Productivity at Enveda —Biotech Innovation with Big Pharma Efficiency
“Most drug discovery projects follow a standard life cycle (left). Any slow step will slow down the entire process, resulting in drug discovery productivity losses. Efficiency gains must address the rate-limiting steps….
“Most drug discovery projects follow a standard life cycle (left). Any slow step will slow down the entire process, resulting in drug discovery productivity losses. Efficiency gains must address the rate-limiting steps….
Enveda Biosciences Systematically Harnesses Untapped Potential of Nature’s Chemistry to Develop Next-Gen Therapeutics
SAN FRANCISCO–(BUSINESS WIRE)–Enveda Biosciences today announced its seed round of funding in the amount of $4.9 million led by True Ventures, with participation from Wireframe Ventures, Village Global and angel investor Chris Gibson (co-founder and CEO of Recursion)….
SAN FRANCISCO–(BUSINESS WIRE)–Enveda Biosciences today announced its seed round of funding in the amount of $4.9 million led by True Ventures, with participation from Wireframe Ventures, Village Global and angel investor Chris Gibson (co-founder and CEO of Recursion)….
Mass spectrometry searches using MASST
Introduced in 1990, a tool for discovering related protein or gene sequences named Basic Local Alignment Search Tool (BLAST) enabled researchers to query ….
Introduced in 1990, a tool for discovering related protein or gene sequences named Basic Local Alignment Search Tool (BLAST) enabled researchers to query ….
Bioactivity-Based Molecular Networking for the Discovery of Drug Leads in Natural Product Bioassay-Guided Fractionation
It is a common problem in natural product therapeutic lead discovery programs that despite good bioassay results in the initial extract, the active compound(s) may not be isolated during subsequent bioassay-guided purification.….
It is a common problem in natural product therapeutic lead discovery programs that despite good bioassay results in the initial extract, the active compound(s) may not be isolated during subsequent bioassay-guided purification.….
ARTEMISININS, MALARIA, AND THE QUEST TO SYSTEMATIZE COLLABORATION BETWEEN NATURE AND SCIENTISTS (CURES AND NOBEL PRIZES)
by Bryan Norman
“Over 3,500 year ago, ancient Sumarians and Egyptians chewed willow bark to relieve pain and fever. Today, aspirin is the most widely used drug on the planet.”…
by Bryan Norman
“Over 3,500 year ago, ancient Sumarians and Egyptians chewed willow bark to relieve pain and fever. Today, aspirin is the most widely used drug on the planet.”…
Exclusive: Enveda Biosciences Announces $4.9M Seed To Create Medicinal Plant Database
Enveda Biosciences has raised a seed round of $4.9 million to build what it touts to be the “world’s largest database of anthropological, chemical and biological data from medicinal plants.”
Enveda Biosciences has raised a seed round of $4.9 million to build what it touts to be the “world’s largest database of anthropological, chemical and biological data from medicinal plants.”
Fulfilling the Promise of Natural Products with Technology: Discovering the Next Generation of Small Molecules
by Matt Healy
“In twenty years of Big Pharma experience, I have seen both the promise of small-molecule Drug Discovery (helping take four molecules all the way from Lead Discovery through Preclinical Development…
by Matt Healy
“In twenty years of Big Pharma experience, I have seen both the promise of small-molecule Drug Discovery (helping take four molecules all the way from Lead Discovery through Preclinical Development…
Global chemical effects of the microbiome include new bile-acid conjugations
A mosaic of cross-phylum chemical interactions occurs between all metazoans and their microbiomes….
A mosaic of cross-phylum chemical interactions occurs between all metazoans and their microbiomes….
Celebrating the departure of an outstanding employee
A few weeks ago, Viswa Colluru, a Senior Product Manager at Recursion, scheduled time with me to share that he would be leaving Recursion….
A few weeks ago, Viswa Colluru, a Senior Product Manager at Recursion, scheduled time with me to share that he would be leaving Recursion….